Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Entain CEO steps down after just five months

(Sharecast News) - Sports betting and gaming group Entain has revealed that chief executive Gavin Isaacs has left the company with immediate effect after just five months. Entain, which runs brands like Coral, Ladbrokes and Foxy Bingo as well part-owning the BetMGM brand in the US, did not disclose a reason for the abrupt departure, but said that the decision was "by mutual agreement".

He will be replaced by non-executive chair Stella David on an interim basis until a permanent replacement has been found.

"Entain is making strong progress in delivering our strategic priorities. We would like to thank Gavin for his contribution," David said in a short statement.

This won't be the first time that David has stepped into the interim CEO role. She served as leader between December 2023 and September 2024 after the exit of former CEO Jett Nygaard-Anderson following the £600m settlement following historic allegations of bribery facing the Turkish business.

Entain used Monday's statement to reiterate its guidance for 2024 ahead of its annual results on 6 March, stating that full-year EBITDA should be at the top end of £1,040m-£1,090m target range as previously announced. The company also said it was "comfortable" with market expectations for this year.

"The board and management remain aligned on the group's focus on operational excellence and maximising shareholder value. I look forward to leading the business as we continue to accelerate our performance," David said.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.